Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

  • Awaiting development
  • GID-TA11692
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Baricitinib within its marketing authorisation for treating alopecia areata ID6541